Detailed 25-page report on Mannkind Corporation (symbol: MNKD) covering everything of importance about Mannkind. It covers all necessary background, their upcoming drug Technosphere Insulin, the ins-and-outs of inhaled insulin and their competition, the relevant clinical trials, Mannkind's financial condition, and the risks of investing in them. Great for anyone considering investing in Mannkind or for anyone looking for a good opportunity to invest in the biotech sector! Current as of May 30, 2008. 10,318 words.